Psilocybin, a prodrug of psilocin found in magic mushrooms, has garnered significant attention as a potential rapid-acting antidepressant when delivered in the form of psilocybin-assisted therapy. The existing evidence is undoubtedly promising, but far from conclusive, as previous studies were limited by their design, small sample sizes, or were conducted in a depressed population in the context…


Previous articlePharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations
Next articleMYND Life Sciences Inc. Establishes Scientific Advisory Board